ICP-CL-00303
ClinicalTrials.gov Identifier |
NCT04565275 |
Institution Name |
Arizona Oncology-HOPE Division |
Institution Address (Street) |
603 N. Wilmot Rd., #151 |
Institution City |
Tuscon |
Institution State |
Arizona |
Institution ZIP Code |
85711 |
Institution Country |
United States |
Institution Phone |
(520) 668-5678 |
Institution Website |
https://arizonaoncology.com |
Additional Institutions |
Rocky Mountain Cancer Centers, Aurora, Colorado Mid Florida Hematology, Orange City, Florida Minnesota Oncology HematologyAll updated information can be found on Clinicaltrials.gov: https://clinicaltrials.gov/ |
Principal Investigator |
Sudhir Manda |
Principal Investigator Phone |
(520) 668-5678 |
Principal Investigator Email |
stacey.kimbell@usoncology.com |
Study Coordinator |
Stacey Kimbell |
Study Coordinator Phone |
(520) 668-5678 |
Study Coordinator Email |
stacey.kimbell@usoncology.com |
Study Overview |
1. Overview: ICP-192 is a novel, irreversible pan-FGFR inhibitor may overcome on-target resistance to first generation FGFR inhibitors (erdafitinib, pemigatinib, rogaratinib, infigratinib, derazatinib). ICP-192 is a highly selective pan-FGFR inhibitor, and has improved safety profiles in comparison to the first generation FGFR inhibitors. |
Enrollment Information |
Active/Recruiting |
Study Start Date |
20200925 |
Study End Date |
20240415 |
Study Purpose |
|
Inclusion Criteria |
|
Exclusion Criteria |
|
Required Tests Prior to Study |
|
Potential Side Effects |
|
Financial Assistance Available |
No |